Table 2 Univariate Kaplan-Meier Survival Analysis according to different clinical characteristics and gene status of oncogenes and tumor suppressor genes from patients with CRC
N | Medium survival (months) (CI 95%) | Log-rank | p | |
|---|---|---|---|---|
Sex | ||||
Male | 12 | 36.4 (26.3–46.6) | 0.450 | 0.502 |
Female | 34 | 42.1 (35.8–48.4) | ||
Age | ||||
< 60 years | 18 | 47.4 (40.5–54.3) | 3.286 | 0.070 |
≥ 60 years | 28 | 33.9 (27.6–40.2) | ||
Stage I / II / III | 28 | 44.2 (37.8–50.6) | 0.669 | |
IV | 18 | 31.8 (24.0–39.6) | 0.413 | |
Tumor site | ||||
Ascending and transverse colon | 15 | 35.9 (27.1–44.7) | ||
Descending and sigmoid colon | 16 | 42.9 (33.4–52.5) | 0.464 | 0.142 |
Rectum | 15 | 36.5 (30.0–43.0) | ||
Gene PIK3CA Wild type | 14 | 42.6 (34.4–50.8) | 0.936 | 0.333 |
Mutated | 15 | 33.9 (25.5–43.4) | ||
Gene KRAS | ||||
Wild type | 15 | 43.3 (35.7–50.9) | 1.797 | 0.180 |
Mutated | 19 | 33.5 (25.5–41.5) | ||
Gene NRAS | ||||
Wild type | 24 | 38.5 (31.4–45.6) | 0.251 | 0.617 |
Mutated | 5 | 39.0 (24.6–53.4) | ||
Gene BRAF | ||||
Wild type | 24 | 38.2 (31.0–45.5) | 0.426 | 0.514 |
Mutated | 5 | 39.8 (26.7–52.8) | ||
Gene EGFR | ||||
Wild type | 5 | 28.8 (22.6–35.1) | 0.149 | 0.700 |
Mutated | 24 | 38.5 (31.3–45.8) | ||
Gene APC | ||||
Wild type | 13 | 44.5 (36.7–52.3) | 1.983 | 0.159 |
Mutated | 16 | 32.6 (23.8–41.3) | ||
Gene PTEN | ||||
Wild type | 21 | 38.3 (30.6–46.0) | 0.257 | 0.612 |
Mutated | 8 | 38.1 (27.2–49.0) | ||
Gene SMAD4 | ||||
Wild type | 20 | 40.9 (33.4–48.4) | 0.649 | 0.421 |
Mutated | 9 | 38.1 (22.2–45.0) | ||
Gene FBXW7 | ||||
Wild type | 19 | 39.3 (31.5–47.0) | 0.007 | 0.934 |
Mutated | 10 | 35.8 (25.0–46.6) | ||
Total mutations (Oncogenes and Tumor Suppressors) | ||||
< 5 mutations | 20 | 41.0 (33.5–48.4) | 0.649 | 0.421 |
> 5 mutations | 9 | 33.6 (22.2–45.0) | ||